Development · 9 Sep 2026

PL Capital reports that the Fortis Healthcare share price outlook is unlikely to be impacted by the probe directed by the Delhi High Court last week.

1 publisher has reported this development. Each act of reporting is below, cited.

The record

livemint.com8 Sep 2026

A single act of reporting so far, corroborating sources join this record as they publish.

Fortis Healthcare

₹785.00

▲ +1.95%

Close (EOD), as of 1 Oct 2026 · source

Fortis Healthcare: results, dividends, orders, the full cited record →

More on Fortis Healthcare

Hospital stocks extended losses for a second session on October 1 as concerns over potential medicine pricing controls continued to weigh on the sector.

2 Oct 2026 · 1 publisher

Hospital stocks, including Apollo Hospitals, Fortis Healthcare, and Krishna Institute of Medical Sciences (KIMS), fell up to 6% after the Supreme Court raised concerns over steep mark-ups on medicines sold through corporate hospitals.

30 Sep 2026 · 2 publishers

Hospital stocks Apollo Hospitals Ltd., Fortis Healthcare Ltd., Max Healthcare Ltd., Krishna Institute of Medical Sciences Ltd., Narayana Health Ltd., and Global Health Ltd. were trading with losses between 5% to 6% on Wednesday, September 30.

30 Sep 2026 · 1 publisher

Hospital and pharma stocks experienced significant selling pressure after the Supreme Court expressed concerns about high mark-ups on essential medicines, especially cancer drugs, calling the price differences "carnage."

30 Sep 2026 · 1 publisher

Hospital stocks came under pressure on Wednesday after the Supreme Court sought the Centre's response on whether a uniform cap should be imposed on the retail prices of medicines and medical devices.

30 Sep 2026 · 1 publisher

Every claim carries its citation

This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.